Clinical Decision Making for Treatment of Diabetic Macular Oedema with DEX Implant: a Consensus Paper

Currently two intravitreally applied corticosteroids (dexamethasone and fluocinolone) are licensed in Germany for treatment of diabetic macular oedema (DME). The use of DEX implant for DME in daily clinical practice has not been defined in detail. Following a Delphi panel survey, a group of retina e...

Full description

Saved in:

Bibliographic Details
Published in:	Klinische Monatsblatter fur Augenheilkunde Vol. 238; no. 1; p. 73
Main Authors:	Augustin, Albert J, Feltgen, Nicolas, Haritoglou, Christos, Hoerauf, Hans, Maier, Mathias M, Mardin, Christian Yahya, Schargus, Marc
Format:	Journal Article
Language:	German
Published:	Germany 01.01.2021
Subjects:	Angiogenesis Inhibitors - therapeutic use Clinical Decision-Making Consensus Dexamethasone - therapeutic use Diabetes Mellitus Diabetic Retinopathy - diagnosis Diabetic Retinopathy - drug therapy Drug Implants Germany Glucocorticoids - therapeutic use Humans Intravitreal Injections Macular Edema - drug therapy Macular Edema - etiology Vascular Endothelial Growth Factor A Germany
ISSN:	1439-3999, 1439-3999
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!